International Journal of Innovative Technologies in Social Science

e-ISSN: 2544-9435

Operating Publisher
SciFormat Publishing Inc.
ISNI: 0000 0005 1449 8214

2734 17 Avenue SW,
Calgary, Alberta, T3E0A7,
Canada
+15878858911
editorial-office@sciformat.ca

ARTICLE TITLE	CARDIOVASCULAR EFFECTS OF ONCOLOGY THERAPIES

DOI	https://doi.org/10.31435/ijitss.2(50).2026.5087
RECEIVED	11 February 2026
ACCEPTED	21 May 2026
PUBLISHED	03 June 2026

CARDIOVASCULAR EFFECTS OF ONCOLOGY THERAPIES

Agnieszka Giza *(Corresponding Author, Email: agnieszka.giza12@wp.pl)*
Independent Public Hospital No. 4 in Lublin, Lublin, Poland
ORCID ID: 0009-0002-5741-3482

Urszula Marzec
Stefan Cardinal Wyszyński Provincial Specialist Hospital SPZOZ in Lublin, Lublin, Poland
ORCID ID: 0009-0000-6348-184X

Aleksandra Cyrkler
Stefan Cardinal Wyszyński Provincial Specialist Hospital SPZOZ in Lublin, Lublin, Poland
ORCID ID: 0009-0001-6865-7450

Natalia Cieślak
Medical University of Lublin, Lublin, Poland
ORCID ID: 0009-0004-6355-8164

Karol Dąbek
Municipal Hospital, John Paul II, Rzeszów, Poland
ORCID ID: 0009-0005-6152-3870

Eliza Rajca
Wojewódzki Szpital Zespolony, Kielce, Poland
ORCID ID: 0009-0005-6024-4298

Paulina Giza
Medical University of Warsaw, Warsaw, Poland
ORCID ID: 0009-0004-7637-5906

Karolina Wymoczył
Stefan Cardinal Wyszyński Provincial Specialist Hospital SPZOZ in Lublin, Lublin, Poland
ORCID ID: 0009-0004-7326-8013

Kamila Czyżak
Municipal Hospital, John Paul II, Rzeszów, Poland
ORCID ID: 0000-0002-8866-5810

Agata Chodkowska
Medical University of Lublin, Lublin, Poland
ORCID ID: 0009-0000-5006-3040

ABSTRACT

Cancer patients' prognosis all around the world has been much improved by treatments including conventional chemotherapy, targeted therapy, and immunotherapy. The benefits of these choices, however, come with their own set of problems; they often lead to a lot of heart problems, which are called cancer treatment-related cardiotoxicity (CTR-C). This study provides a thorough examination combining the most recent results on a number of important aspects including the prevalence of cardiotoxicity, its underlying pathophysiology, and the critical need of strong monitoring systems.

For this review, information was carefully looked at from a lot of places, including systematic reviews, meta-analyses, randomized controlled trials, observational research, and guideline papers. Depending on the dosage, anthracyclines have been found to induce left ventricular dysfunction, arrhythmias, and maybe even heart failure in certain persons. Furthermore, HER2-targeted medicines, while often exhibiting reversible side effects, are known for raising the risk of cardiotoxicity, especially in patients who have undergone anthracycline therapy before. Immune checkpoint inhibitors (ICIs) present a particular set of difficulties since they are linked with immune-mediated myocarditis, arrhythmias, pericardial disorders, and, on rare events, vasculitis, with symptoms usually during the first cycles of treatment.

The current research clearly emphasizes the critical importance of baseline cardiovascular examinations using a range of imaging modalities and biomarkers to help to detect cardiotoxicity early in individuals undergoing cancer therapy.

Though this field has progressed, more study is required to improve monitoring techniques and develop individualized preventive plans to reduce the cardiovascular hazards related to cancer therapies.

KEYWORDS

Cardio-oncology, Chemotherapy, Immunotherapy, Cardiotoxicity, Myocarditis, Heart Failure

CITATION

Agnieszka Giza, Urszula Marzec, Aleksandra Cyrkler, Natalia Cieślak, Karol Dąbek, Eliza Rajca, Paulina Giza, Karolina Wymoczył, Kamila Czyżak, Agata Chodkowska. (2026) Cardiovascular Effects of Oncology Therapies. *International Journal of Innovative Technologies in Social Science*. 2(50). doi: 10.31435/ijitss.2(50).2026.5087

Introduction

Background

Cancer is still a significant cause of sickness and death all around the world. Shocking statistics show that in 2020, there were about 19.3 million new cases of cancer and 10 million cancer-related deaths. According to a thorough 2021 Sung et al. analysis, projections point to a significant increase in these figures over the following few decades. This alarming trend emphasizes the pressing need for continuous cancer research and discoveries as well as exploration.

In recent years, great advances in cancer treatments have given fresh hope for people fighting many different kinds of cancer. More specialized approaches including targeted medicines and immunotherapy join conventional chemotherapy—which has long been a cornerstone of cancer treatment—among these advancements. Particularly, medications including doxorubicin and epirubicin known as anthracyclines have evolved into vital elements in treatment regimens for several solid tumors and blood malignancies. Furthermore significantly changing the course of breast cancer treatment are targeted medicines, especially those that target the HER2 protein, which improve patient outcomes and general quality of life.

Moreover, the development of immunotherapy, noted by the emergence of immune checkpoint inhibitors (ICIs) and CAR-T cell treatments, points to a major change in the way blood malignancies as well as solid tumors are treated. A significant improvement in cancer treatment, these innovative approaches use the power of the immune system to find and kill cancer cells.

Even with these developments and the possible advantages they bring, it is important to note the negative effects cancer therapies may have on the heart system, causing a range of problems together known as cancer therapy-related cardiotoxicity (CTR-C). Among other difficulties, this complex disorder can cause left ventricular (LV) malfunction, heart failure, arrhythmias, pericardial issues, hypertension, vascular occurrences, and thromboembolic events. Rising knowledge of CTR-C as a significant clinical concern has then led to the development of cardio-oncology, a particular discipline meant to combine the body of knowledge from cardiology with that from oncology. This holistic strategy seeks to improve patient outcomes by closely tracking and treating cardiovascular health in those with cancer, therefore enhancing their general well-being both during and after their treatment.

Epidemiology of Cardiotoxicity

Originally, anthracyclines were the first class of chemotherapy medications found to possibly damage the heart. Depending on elements including total dosage, age, gender, pre-existing heart disease, and other treatments like radiotherapy (Cardinale et al., 2015), the chance of patients treated with anthracyclines developing symptomatic heart failure varies from 5% to 26%. Epidemiological studies show that elderly people, women, and those with pre-existing hypertension or diabetes are particularly susceptible to heart problems brought on by anthracyclines.

In people with HER2-positive breast cancer, targeted treatments for HER2 like trastuzumab have improved patient survival rates. Still, studies reveal that between 3% and 10% of patients may experience reversible left ventricular dysfunction, with a higher probability if they have undergone anthracycline therapy earlier (Piccart-Gebhart et al., 2005; Ewer & Ewer, 2010). Importantly, combining anthracyclines with HER2 inhibitors or using them one after the other greatly increases the possibility of heart damage, hence the need for a careful assessment of total risks.

Immune checkpoint inhibitors (ICIs) like anti-PD-1, anti-PD-L1, and anti-CTLA-4 antibodies have changed the way many cancers are treated. Meta-analyses show that about 3% of patients who get ICIs have some kind of heart problem. The most serious side effect is immune-mediated myocarditis, which can kill 40–50% of patients. This shows how important it is to quickly find and treat any heart problems (Salem et al., 2018). CAR-T cell therapy, which is becoming more common for blood cancers, can cause cytokine-release syndrome (CRS) in 10–20% of patients (Hay et al., 2019). Mechanisms of Cardiotoxicity.

1. Anthracycline-Induced Cardiotoxicity

Anthracycline-induced cardiotoxicity is a complex and complex problem that causes a lot of trouble in clinical oncology. It includes both direct damage to the heart muscle and other indirect ways that make cardiac function worse.

Oxidative stress is a major cause of this kind of cardiotoxicity. Certain cancer-fighting drugs called anthracyclines are known to generate reactive oxygen species (ROS) when they are broken down. Too much of these ROS can harm cardiomyocytes by destroying important structures including cell membranes, mitochondrial DNA, and several proteins present in the heart cells. This oxidative damage can eventually cause severe cellular malfunction, therefore impairing the heart's ability to function effectively and contract.

The inhibition of topoisomerase-IIβ—an enzyme critical for DNA repair—is yet another aspect influencing cardiotoxicity from anthracyclines. Anthracyclines block the usual DNA repair process inside cardiomyocytes by interfering with the action of topoisomerase-IIβ. In these cardiac muscle cells, such damage can induce apoptosis—programmed cell death—further reducing heart performance and increasing heart failure risk.

Furthermore, mitochondrial dysfunction is very important for the development of cardiotoxic effects. A decrease in ATP production in the mitochondria compromises the heart's contractile ability as cardiomyocytes rely largely on ATP for energy during their contraction. The general decline of myocardial health is accelerated by this deficiency in energy, which lowers the pumping efficiency of the heart and stimulates cell death.

Additionally, contact with anthracycline causes sarcomere disorganization. Decreased systolic performance follows structural alterations in sarcomeres, the basic contractile elements of muscle fibres. This interference reduces the heart's ability to contract correctly, therefore exacerbating the negative effects of the medication on cardiac performance.

Concerning risk variables, developing anthracycline cardiotoxicity is consistently shown to be most strongly predicted by cumulative dosage. Research by Cardinale et al. in 2015 have especially shown that the likelihood of having cardiotoxicity rises over 20% when the total dosage of doxorubicin, among the most often used anthracyclines, surpasses 550 mg/m2.

Furthermore, patient-specific traits strongly affect the probability of developing cardiotoxicity brought on by anthracycline. Older age, being female, having present cardiovascular problems, and a history of past chest radiation therapy all raise one's likelihood of suffering cardiotoxic consequences. These unique risk variables highlight the need of tailored methods in monitoring and caring for patients undergoing anthracycline treatment.

2. HER2-Targeted Therapy

Essential in cancer therapy, HER2 inhibitors block the neuregulin-1/ErbB2 signaling system, which is vital for heart cell survival, especially during physical or pathological stress. Unlike traditional chemotherapy medications like anthracyclines, which are recognized to cause long-lasting damage to cardiac tissue, HER2-targeted treatments can cause reversible left ventricular dysfunction, therefore preventing any permanent damage to the anatomy of the heart. Early identification and constant monitoring of heart health are especially important since this ability to cause reversible left ventricular dysfunction stresses their relevance.

Echocardiography is really important to assist in early diagnosis. Among echocardiographic methods, measuring worldwide longitudinal strain (GLS) is especially helpful since it can identify mild myocardial damage early on. This is especially crucial because GLS can show changes in heart function before a major decrease in left ventricular ejection fraction (LVEF), a frequent measure of poor cardiac performance. As a result, patients on HER2-targeted treatments should have frequent echocardiographic tests, with a particular eye on GLS values, to actively check heart function and enable timely interventions if required.

3. Immunotherapy-Related Cardiotoxicity

Immune-related side effects brought on by immune checkpoint inhibitors (ICIs)—which comprise several medicinal compounds including anti-PD-1, anti-PD-L1, and anti-CTLA-4 antibodies—can significantly affect cardiovascular health. Such adverse effects may include myocarditis, arrhythmias, pericarditis, and, in rare cases, vasculitis. Multiple mechanisms define the complex underlying pathophysiology of these heart problems:

T-cell activation first happens against antigens specific to tumors that are also found in heart tissues, which causes an immune response that hurts the heart by mistake. Inflammation brought on by cytokines within the heart muscle worsens this immune activation; notably, important cytokines including IL-6, TNF-α, and IFN-γ are essential for this process. Moreover, endothelial cells' activation causes microvascular damage, which could provide a substrate for arrhythmias and therefore increases the risk for aberrant heart rhythms.

Understanding that ICIs-related myocarditis typically shows early in treatment and can be seen in the first one or two cycles of therapy is very important. As outlined in the study by Zhang et al. (2020), this early occurrence calls for careful and watchful clinical observation as well as biochemical tests to proactively identify and handle any possible cardiac problems.

On the other hand, CAR-T cell therapy has its own set of problems, the most important of which is the chance of getting cytokine release syndrome (CRS). This syndrome is defined by a notable rise of pro-inflammatory cytokines including IL-6, IFN-γ, and GM-CSF produced by the treatment, which might cause a broad spectrum of clinical signs including low blood pressure, rapid heart rate, capillary leak syndrome, and acute myocardial stunning. Particularly in severe CRS cases, the clinical indications can closely resemble those of cardiogenic shock, hence requiring transfer to intensive care units for quick treatment and the use of focused immunosuppressive treatments to reduce these severe consequences.

Risk Factors and Patient Stratification

In cardio-oncology—which aims to satisfy the particular cardiovascular needs of cancer patients—effective risk categorization is essential for offering premium, individualized care. In order to reach this goal, it is imperative to evaluate a spectrum of well-known risk factors that could cause heart-related problems in people getting cancer treatment.

Among these markers, demographic aspects especially count. Particularly vulnerable are women aged 65 and older who have had anthracycline therapy; especially they may be at higher risk. Furthermore, people of African descent have a higher natural risk of heart failure, therefore emphasizing the need of culturally sensitive assessments in this group.

Apart from demographic considerations, a main feature of risk assessment is the presence of comorbidities. Undergoing cancer treatment, patients with pre-existing heart disease, high blood pressure, diabetes, hyperlipidemia, or ongoing health problems including hypertension, diabetes, hyperlipidemia, can increase the likelihood of cardiac problems. Therefore, a part of the evaluative framework is for medical practitioners to thoroughly evaluate these underlying diseases.

Furthermore, risk stratification has to consider particular features of therapy. For instance, a high cumulative exposure to anthracyclines and the use of sequential or combination treatments, like anthracyclines combined with HER2 inhibitors, can significantly influence cardiovascular risk. Another important factor to think about is if you've had chest radiation therapy before. This is because it could make you more likely to have heart problems later on.

Finally, evaluating a person's risk of cardiovascular issues depends mostly on genetic variables. Research indicates that particular polymorphisms in genes like topoisomerase-IIβ, NAD(P)H oxidase, as well as several genes connected to oxidative stress, could raise this risk. Customizing treatment plans depends on an awareness of these hereditary factors.

Including these several aspects into customized care programs not only enables medical practitioners to better cardiovascular monitoring but also enables quick interventions if required. Adopting this whole approach helps professionals to improve patient outcomes in the field of cardio-oncology, hence leading to more efficient management of cardiovascular risks related to cancer therapies.

1. Imaging Modalities

Early diagnosis of cardiac toxicity linked to chemotherapy (CTR-C) depends on imaging. Echocardiography is used as the main way to check the left ventricular ejection fraction (LVEF). Adding global longitudinal strain (GLS) gives very important information for spotting subtle heart damage that might not show up on normal imaging tests. Cardiac MRI (MRI) is also regarded as the gold standard for diagnosing myocarditis. Particularly good at exposing major pathological features including myocardial inflammation, fibrosis, and edema, this imaging technique enables a more thorough evaluation of heart health. Furthermore, given the possible cardiotoxic effects of HER2-targeted therapies, speckle-tracking echocardiography is becoming more and more recognized for its capacity to detect early myocardial injury, particularly in individuals undergoing HER2-targeted treatments—which is a crucial point to keep in mind.

2. Biomarkers

Along with imaging, biomarkers provide more knowledge that can highlight heart muscle damage even before apparent functional decline is noted. Particularly, cardiac troponins—especially cTnI and cTnT—have demonstrated remarkable sensitivity in identifying myocardial injury brought on by anthracyclines, hence they are indispensable for supervising the cardiac state of cancer patients. NT-proBNP is yet another important biomarker since it measures the degree of stress in the heart muscle and is closely related to left ventricular dysfunction. Moreover, fresh biomarkers such as galectin-3, ST2, and particular microRNAs (miR-1 and miR-133) might greatly enhance our capacity to forecast cardiac events, so enhancing patient care strategies via speedier and more efficient interventions.

3. Monitoring Frequency

Suggested monitoring schedules are crucial to guarantee the safety and efficacy of heart health assessments done on people receiving cancer treatments. Before beginning any treatment program, it's essential to do a thorough first assessment that acts as a benchmark for later reference. After this first examination, it is advised to get echocardiography every three months during the course of treatment, along with more checks six to twelve months following treatment completion. Moreover, biomarker monitoring should occur before each chemotherapy cycle for patients classified as high-risk; this should be even more emphasized for those receiving immunotherapy (ICIs) or CAR-T cell treatments as these modalities could raise the possibility of cardiac problems. Reducing the likelihood of adverse consequences and maintaining best heart function in vulnerable patient populations depends on such rigorous monitoring rules.

Preventive Strategies

1. Pharmacologic Interventions

Many medicinal compounds have been found and extensively tested for their heart-protective properties. This highlights their potential role in lowering heart-related problems.

- Dexrazoxane: This revolutionary iron-binding molecule has demonstrated an outstanding ability to lower reactive oxygen species (ROS), which are known to damage cells in the heart. Crucially, the U.S. Food and Drug Administration (FDA) has approved it particularly to stop cardiotoxicity caused by anthracyclines—a common side effect connected with certain chemotherapy regimens.

- By effectively lowering neurohormonal stimulation—a component that causes stress on the heart—ACE Inhibitors and Angiotensin II Receptor Blockers (ARBs) are essential for supervising cardiovascular health. They have also shown to reduce left ventricular (LV) structural alterations, which are essential for keeping heart form and function over a long time.

- Beta-Blockers (like carvedilol and nebivolol): These medications serve as defense mechanisms against stress brought on by catecholamines, which might negatively impact heart function. Moreover, they have been connected to improvements in left ventricular function, so promoting general cardiac health.

Statins: Growing studies keep showing how good they are for the heart. Statins are usually known for lowering cholesterol. Their diverse benefits include significant antioxidant and anti-inflammatory qualities that improve cardiovascular health outcomes.

2. Immunotherapy-Specific Interventions

Immune-related side effects, especially myocarditis brought on by immune checkpoint inhibitors (ICIs), call for a tailored and cautious approach in administration. The increasing use of these therapies in oncology has led to notable improvements in patient outcomes, but the associated adverse effects, particularly myocarditis, necessitate enhanced vigilance and individualized management strategies. Recognizing the potential for adverse cardiac events is essential for healthcare providers, as early detection can significantly influence the overall prognosis and recovery experiences of affected patients.

- Prompt Identification and Corticosteroid Treatment: Early symptom recognition is especially important if myocarditis results from ICIs. Symptoms such as chest pain, dyspnea, or new-onset fatigue can present subtly, often mimicking other conditions. Therefore, thorough assessment, including electrocardiograms and echocardiograms, is crucial for accurate diagnosis. The main way to treat this problem is with corticosteroids. They work by quickly calming inflammation and lowering damage to the heart muscle. Administration of corticosteroids can lead to rapid improvements in symptoms, effectively alleviating cardiac stress and promoting recovery. It is paramount for clinicians to monitor patients closely during this period to gauge treatment efficacy and make adjustments as necessary.

- Immunosuppressive Therapy: If patients do not react to steroids, more extensive immunosuppressive medicines might be considered. Alternative immunosuppressive therapies, such as mycophenolate mofetil, infliximab, or abatacept, may be necessary to modulate immune responses more aggressively. These therapies can help manage continuous symptoms and lessen the unfavorable effects of ICIs. However, each option comes with its own set of potential risks and benefits that must be weighed carefully. Regular follow-up consultations are essential to assess the patient's response to therapy, monitor for potential complications, and adjust treatment plans accordingly. This proactive approach can help mitigate the risks associated with extended treatment while ensuring that patients receive the necessary support during their recovery.

- Re-challenge therapy: Deciding to start immunotherapy again after developing myocarditis is complex and should be done for each person differently. Clinicians must approach the re-challenge of ICIs with caution, bearing in mind the broad spectrum of individual patient responses and the intricacies of immune-related adverse events. Before deciding, one must assess several factors including the strength of the first reaction, the patient's improvement rate, and the patient's general risk profile. Comprehensive discussions with patients about the potential risks, benefits, and uncertainties surrounding re-initiation of therapy are essential for informed decision-making. Continuous engagement in shared decision-making fosters a collaborative environment where patients feel empowered and informed about their treatment journey, ultimately leading to better adherence and outcomes. As the understanding of the mechanisms behind ICI-associated myocarditis evolves, ongoing research will likely provide additional insights into optimal management strategies, paving the way for improved care practices in the clinical setting.

Clinical Implications

The combination of specialized knowledge in cardiology and oncology greatly improves the early recognition of possible complications, reduces breaks in treatment that might hinder patient care plans, and enhances survival rates for individuals fighting cancer. This multidisciplinary approach is critical, as it addresses the complex interactions between cancer therapies and cardiovascular health, making the integration of cardiology insights invaluable in oncology practice. To effectively assist high-risk patients within this combined approach, several essential tactics may be implemented, including:

• Designing and carrying out individualized monitoring plans fit to each patient's unique health issues and treatment methods enables quick evaluations and interventions when required. These personalized plans take into account the specific types of cancer treatments a patient is undergoing, their overall medical history, and unique responses to previous therapies. By tailoring monitoring strategies, healthcare providers can ensure that any deviations from the expected health trajectory are identified promptly, allowing for timely adjustments to treatment as necessary.

• Ensuring patients get complete care that emphasizes both cardiology and cancer health by offering preventative medical treatments meant to lower the likelihood of cardiotoxic side effects related to particular cancer treatments is paramount. This can involve proactive measures, such as administering cardioprotective medications prior to starting chemotherapy or radiation therapy, and regular cardiovascular assessments throughout the cancer treatment timeline. The emphasis on prevention not only improves the quality of life for patients but can also lead to better treatment outcomes, as patients are less likely to experience treatment interruptions or complications stemming from cardiac issues.

- By providing thorough education and skill development for oncology staff, their capacity to spot early signs and symptoms of cardiotoxicity is enhanced, therefore enabling them to respond fast to prevent further problems for their patients. This education should emphasize the significance of recognizing symptoms early, understanding the underlying mechanisms of cardiotoxicity, and coordinating care with cardiologists. Training simulations, workshops, and continuing education can empower oncology professionals, making them more vigilant in monitoring potential cardiovascular reactions to cancer treatments.
- Implementing the use of electronic health records (EHR) linked with automated notifications that highlight any abnormal troponin levels or notable decreases in left ventricular ejection fraction (LVEF) enables medical practitioners to rapidly handle any developing cardiovascular problems. This technological integration streamlines communication among the healthcare team, ensuring that critical information regarding a patient's heart health is readily available and acted upon. Moreover, enhancing data sharing between oncology and cardiology departments fosters a collaborative environment where health care providers can work together more efficiently, creating a unified front against cancer and its side effects.

Medical professionals may encourage a more cohesive and nimble treatment environment by using these methods, therefore stressing the general health and welfare of patients going through cancer treatment challenges. By reinforcing the interconnectedness of the heart and cancer therapies, these strategies not only safeguard patient health but also exemplify a progressive model of integrative care that can be adapted to various complex medical scenarios, ultimately leading to improved patient experiences and outcomes.

Limitations of Current Evidence

While there has been notable improvement in the field, it is important to remember that the current data shows a number of major limits that call for careful study.

One of the biggest challenges first is the variety of research methods used. Differences in the people in the studies, the way they measured outcomes, and the amount of time they were followed up for make it hard to compare and use the results of different studies. Such variations make it more difficult to reach general conclusions applicable to several patient groups and treatment modalities.

Moreover, incomplete reporting—especially with regard to subclinical or delayed cardiotoxic effects connected to particular treatment modalities, especially immunotherapy—is a serious issue. Neglect of this kind could result in an underappreciation of cardiovascular risks that develop after the first stages of therapy, therefore influencing patient care and general results.

Furthermore contributing to the ambiguity about the long-term cardiovascular consequences is the short follow-up period seen in several studies. Without long-term observation, it is challenging to fully grasp the long-term consequences of therapies on cardiac health; this puts doctors at a disadvantage when making evidence-based decisions about patient care.

Ultimately, the lack of consistent rules for the monitoring and treatment of cardiovascular problems causes great differences in procedures between different medical facilities. This lack of uniformity not only adds to the difficulty of judging treatment effectiveness but also complicates clinical decision-making as medical professionals may employ different approaches for similar patient scenarios.

To increase the relevance and clarity of cardiovascular safety information for patient groups undergoing different treatment approaches, the healthcare industry has to address these limitations even if developments have actually taken place.

Future Directions

Future studies should concentrate on a few key topics meant to enhance cardiovascular health outcomes and patient care. First off, there has to be a focused effort on producing genetic profiling techniques and predictive biomarkers that allow for patient-specific risk assessment. This would help not only to tailor treatment plans but also to spot people at higher risk for cardiovascular events so enabling faster deployment of preventive measures.

It is also quite important to set consistent monitoring procedures. To ensure uniformity in patient care and to increase the dependability of results across several healthcare settings, this includes the development of standardized imaging methods and a specified timetable for biomarker evaluations. For patients and doctors alike, such consistency would be of great benefit as it would provide more precise guidelines for tracking the effects of treatments and the onset of any cardiac problems.

Also, it is very important to find new things that can protect the heart. This entails evaluating the efficacy and safety of several medication classes, including sodium-glucose co-transporter 2 (SGLT2) inhibitors, neprilysin inhibitors, and targeted anti-inflammatory treatments, with the aim of discovering fresh treatment options that might lessen cardiotoxic risks connected to present treatments.

Evaluating late-onset cardiotoxicity also depends on long-term studies, particularly in individuals treated with immune checkpoint inhibitors (ICIs). These research should seek to expose the long-term cardiovascular effects of such therapies, therefore providing vital information about possible risks and guiding future treatment recommendations.

Finally, one should look into how modern technologies like machine learning (AI) and artificial intelligence (AI) are used in clinical settings. Using these advanced tools helps scientists and medical professionals to more effectively analyze multi-modal patient data, hence improving the ability to properly estimate the likelihood of cardiotoxicity. The discipline of cardiovascular risk management may be transformed and patient safety enhanced by this integration.

Aim

This study tries to give a complete summary of the heart-related adverse effects connected with chemotherapy and immunotherapy, paying particular attention to major points necessary to grasp and properly address these issues. It will first look into the frequency, underlying causes, and risk factors linked to cardiotoxicity to give a thorough explanation of how these side effects show in people going through cancer treatments, and to identify the biological and clinical aspects that raise the likelihood of cardiovascular problems.

Then the study will look at the ways that can be used to find these negative effects early on. This includes things like advanced imaging techniques and the use of some biomarkers that show heart distress or damage. To allow quick response for any developing problems, it will establish best practices for monitoring as well as the need of continuous cardiovascular checkups all through the course of therapy.

Furthermore, the research will evaluate treatment and preventative measures that might be implemented to lower cardiotoxicity in immunotherapy and chemotherapy patients. This section will also go over how well various cardioprotective drugs and lifestyle modifications patients could make help to reduce the cardiovascular risks associated with their cancer treatments.

It will at last provide practical ideas for the establishment of integrated cardio-oncology care teams, stressing the need of coordinated care to improve both heart health and cancer treatment outcomes by means of cooperation between oncologists, cardiologists, and primary care doctors to ensure complete patient management.

Methodology

Peer-reviewed publications were subjected to narrative review. Web of Science, Scopus, and PubMed were among the databases looked upon. "Cardiotoxicity," "chemotherapy," "anthracyclines," "HER2 inhibitors," "immune checkpoint inhibitors," "immunotherapy," "myocarditis," "heart failure," "arrhythmia," "cardio-oncology" are examples of search keywords that include controlled vocabulary (e.g., MeSH) and free-text keywords. Chosen were studies in English documenting adult human cancer patient cardiovascular outcomes. Preclinical animal-only studies were not included. Data gathering mostly concentrated on cardiovascular event frequency, kinds of cardiotoxicity, risk factors, monitoring techniques, and preventative and therapeutic measures.

Results

Cardiotoxicity from Chemotherapy and Targeted Therapies

Anthracyclines: Cardiac damage to myocytes is influenced by dosage, leading to stress through oxidation, issues with mitochondria, and cell death; potential outcomes include silent left ventricular dysfunction, overt heart failure, arrhythmias, or unexpected cardiac death.

HER2-targeted agents: A drop in left ventricular ejection fraction; this decline is usually reversible, particularly if not preceded by extensive cumulative doses of anthracyclines.

Combined/multimodal therapies: The use of several cardiotoxic treatments escalates the risk to the heart; this necessitates meticulous planning of treatment and enhanced observation.

Prevention strategies: Investigations into dexrazoxane, ACE inhibitors, beta-blockers, and statins have been conducted. Dexrazoxane is approved by the FDA to provide protection against cardiotoxicity induced by anthracyclines. ACE inhibitors and beta-blockers might slightly reduce the decrease in LVEF.

Cardiotoxicity from Immunotherapy (Immune Checkpoint Inhibitors)

Incidence and risk: Meta-analyses show that 3% of patients receiving immune checkpoint inhibitors experience some degree of cardiotoxicity; myocarditis and arrhythmias have a notably higher incidence.

Onset: This typically occurs early on — generally within the initial treatment cycles (around 30 to 34 days).

Mechanisms: Immune activation mediated by T-cells, autoimmune myocarditis, and inflammation driven by cytokines.

Other cardiovascular events: Conditions such as pericardial disease, heart failure, vasculitis, and thromboembolism; CAR-T therapy may induce cytokine-release syndrome that can have cardiovascular consequences.

Monitoring, Prevention and Management

Monitoring: Initial evaluation, continuous echocardiogram assessments (LVEF, GLS/strain), cardiac MRI for potential myocarditis. Biomarkers include troponin and NT-proBNP.

Prevention / Cardioprotection: In chemotherapy, protective measures involve dexrazoxane and neurohormonal treatment; for immunotherapy, early identification and immunosuppression for immune-related cardiovascular adverse events are necessary.

Challenges: Though events occur infrequently, severe cases have a significant mortality rate, with underreporting prevailing, absence of uniform guidelines, and doubt regarding the feasibility of re-initiating treatment.

Discussion

1. Overview of Findings

Gathering data from the past 15 years on cardiotoxic consequences connected to cancer treatments, this review mostly covers well-known chemotherapy medicines as well as newer immunotherapeutic alternatives. Although their dose-dependent cardiomyopathy is well proven in several randomized controlled trials and observational studies, anthracyclines continue to be the classic examples of cardiotoxic drugs. Oxidative damage, topoisomerase-IIβ blockade, mitochondrial impairment, and cell death are the processes implicated; these are repeatedly supported by laboratory and clinical studies (Zamorano et al., 2016; Chatterjee et al., 2010).

Especially trastuzumab, agents focusing on HER2 have a distinct cardiotoxicity profile. Unlike anthracyclines, HER2-targeted therapies usually result in temporary left ventricular dysfunction without damaging cardiomyocytes structurally. Still, when taken with anthracyclines, the cardiotoxic effects are synergistic, which highlights how important it is to carefully assess the cumulative risk (Tan-Chiu et al., 2005).

Although immune-related cardiac toxicity may result from immune checkpoint inhibitors (ICIs), they are a major breakthrough in the management of cancer. Meta-analyses show that about 3% of people who get CAR-T cell therapy for blood cancers, which is becoming more common, have cardiotoxicity. The most dangerous side effect is myocarditis, which can cause the heart to malfunction, low blood pressure, and rapid heart rhythms (Hay et al., 2019). CAR-T cell therapy can cause cytokine-release syndrome (CRS), which can cause low blood pressure, fast heart rhythms, and heart problems. Salem et al. (2018) found that CRS can cause death in 40–50% of cases.

2. Mechanisms of Cardiotoxicity

2.1 Chemotherapy-Induced Cardiotoxicity

The cardiotoxicity stemming from anthracyclines is complex, involving several factors:

Oxidative damage: The excessive production of reactive oxygen species (ROS) leads to harm to cardiomyocyte membranes and mitochondrial genetic material.

Topoisomerase-IIβ blockade: Disruption of DNA repair processes results in cell death.

Mitochondrial impairment: Interruptions to ATP synthesis reduce heart muscle contraction.

Sarcomeric disarray: Damage to cardiac fibers diminishes performance during systole.

Accumulated dosing remains the most significant indicator of cardiotoxicity, with risk increasing over 20% at higher cumulative doses of doxorubicin (greater than 550 mg/m²) (Cardinale et al., 2015). Individual patient characteristics, such as age, gender, existing heart conditions, and simultaneous chest radiation treatment, further influence the level of risk.

2.2 HER2-Targeted Therapy

HER2-targeting agents disrupt the neuregulin-1/ErbB2 signaling pathway, which is crucial for maintaining cardiomyocyte health during stressful conditions. The resulting reversible left ventricular dysfunction is typically observed as reductions in left ventricular ejection fraction (LVEF) without tissue damage detectable under microscopy. This reversibility sets apart HER2-related cardiotoxicity from that caused by anthracyclines, highlighting the critical role of early detection through echocardiography and strain imaging technique (Ewer & Ewer, 2010).

2.3 Immunotherapy-Related Cardiotoxicity

ICIs, such as those targeting PD-1, PD-L1, and CTLA-4, can provoke immune-mediated myocarditis, rhythm disturbances, and pericarditis. The underlying mechanisms include:

Activation of T-cells against both tumor-related and heart-related antigens

Cytokine-driven heart inflammation, mainly involving IL-6, TNF-α, and IFN-γ

Activation of endothelial cells, causing potential damage to small blood vessels and creating a risk for arrhythmias

The onset of these effects is quick, frequently occurring within the initial 1 to 2 cycles of treatment, thereby requiring close early monitoring (Zhang et al., 2020).

CAR-T therapies generate CRS, where increased levels of IL-6, IFN-γ, and other inflammatory cytokines lead to low blood pressure, fast heart rate, and heart impairment. Severe cases of CRS may simulate cardiogenic shock, necessitating intensive medical support and focused immunosuppression treatments (Hay et al., 2019).

3. Risk Factors and Patient Stratification

Individualized care in cardio-oncology relies heavily on risk stratification. Recognized risk contributors include:

Demographic variables: Individuals over 65 years old, females (specifically concerning anthracyclines), and those of African descent (who face a higher initial risk for heart failure).

Comorbid conditions: Presence of hypertension, diabetes, dyslipidemia, or a history of ischemic heart disease.

Factors related to therapy: High total doses of anthracycline, treatments involving combinations or sequences (anthracycline alongside HER2 inhibitors), and previous chest radiation therapy.

Genetic susceptibility: Variations in topoisomerase-IIβ or genes related to oxidative stress may heighten vulnerability (Visscher et al., 2020).

4. Monitoring Strategies

Successful monitoring entails a combination of imaging techniques and biomarker assessments, allowing for the prompt identification of early cardiotoxicity.

4.1 Imaging Modalities

Echocardiography: Measurement of left ventricular ejection fraction (LVEF) and global longitudinal strain (GLS) to spot early signs of left ventricular dysfunction.

Cardiac MRI: Considered the benchmark for identifying myocarditis, capable of revealing edema and fibrotic changes.

Speckle-tracking echocardiography: Highly effective for detecting early myocardial damage.

4.2 Biomarkers

Cardiac troponins (specifically cTnI and cTnT): Highly sensitive indicators of myocardial injury caused by anthracyclines.

NT-proBNP: An indicator reflecting myocardial stress that correlates with left ventricular dysfunction.

Emerging biomarkers: Galectin-3, ST2, and microRNAs (such as miR-1 and miR-133) may enhance predictive capacity.

4.3 Monitoring Frequency

Initial evaluation prior to the start of therapy.

Regular echocardiographic assessments: performed every three months during treatment and 6 to 12 months after treatment completion.

Biomarker testing: conducted before each chemotherapy cycle in patients identified as high-risk.

5. Preventive Strategies

5.1 Pharmacologic Interventions

Dexrazoxane: An iron-chelating compound that minimizes reactive oxygen species, approved by the FDA for mitigating anthracycline-related cardiotoxicity.

ACE inhibitors / ARBs: Help reduce neurohormonal stimulation and limit left ventricular remodeling.

Beta-blockers (specifically carvedilol and nebivolol): Provide protection against stress induced by catecholamines.

Statins: New data indicate possible beneficial cardiac effects unrelated to cholesterol lowering.

5.2 Immunotherapy-Specific Interventions

Prompt diagnosis and treatment with corticosteroids for myocarditis triggered by immune checkpoint inhibitors (ICIs).

Use of immunosuppressants (like mycophenolate mofetil and infliximab) for cases resistant to steroids.

Thoughtful evaluation for re-challenging therapy, customized according to severity and recovery status.

6. Clinical Implications

The collaboration between cardiology and oncology specialists fosters earlier detection and minimizes treatment disruptions.

Patients at elevated risk gain from tailored monitoring protocols and pharmaceutical preventative measures.

Training for oncology personnel regarding the initial indicators of cardiotoxicity is crucial, particularly in relation to ICI and CAR-T therapies.

Adoption of electronic health records with automated warnings for concerning troponin levels or decreases in LVEF can lead to improved patient outcomes.

7. Limitations of Current Evidence

Diverse study methodologies and varying patient demographics restrict the ability to make direct comparisons.

There is a lack of reporting on subclinical or belated cardiotoxicity, especially within immunotherapy contexts.

Numerous trials have short follow-up durations; thus, the long-term consequences remain unclear.

Absence of unified monitoring protocols results in inconsistent clinical practices.

8. Future Directions

Advancement of predictive biomarkers and genetic assessments for personalized risk evaluation.

Uniformity in monitoring guidelines, encompassing schedules for imaging and biomarkers.

Examination of innovative cardioprotective medications (like SGLT2 inhibitors and neprilysin inhibitors).

Longitudinal research focusing on cardiotoxicity emerging later on, especially following ICI treatment.

Utilization of artificial intelligence and machine learning to evaluate cardiotoxicity risk through diverse patient data sets.

Conclusions

Oncology faces a significant issue with cardiotoxicity related to cancer treatments. Anthracyclines can lead to myocardial damage that is often irreversible and depends on the administered dose, while therapies targeting HER2 usually result in temporary left ventricular dysfunction. Immune checkpoint inhibitors and CAR-T therapies bring about immune-related cardiotoxic effects, with myocarditis and myocardial injury due to cytokines being notable risks, often associated with high early mortality rates.

Key messages:

Timely identification through imaging techniques (such as echocardiography and cardiac MRI) and biomarker tests (including troponin and NT-proBNP) is vital.

Measures for prevention, which may incorporate dexrazoxane, ACE inhibitors, beta-blockers, and immunosuppressive therapy for ICI/CAR-T treatment, help to reduce risk.

A collaborative approach from cardio-oncology teams is crucial to ensure the effectiveness of cancer treatments while safeguarding cardiovascular health.

Future investigations should prioritize tailored risk assessment, standardized monitoring procedures, predictive biomarkers, and long-term outcomes.

By systematically combining these approaches, healthcare providers can reduce heart-related complications, ensure the continuation of essential cancer treatments, and ultimately enhance both survival rates and the quality of life for patients battling cancer.

All authors have read and agreed to the published version of the manuscript

Funding: This research received no external funding

Data availability statement: Data sharing is not applicable to this article

Conflict of interest: The authors declare no conflict of interest

Declaration of the use of generative AI and AI-assisted technologies in the writing process: In preparing this work, the authors used Google Gemini for the purpose of improving language, grammar correction, text formatting. After using this tool, the authors reviewed and edited the text as needed and accept full responsibility for the substantive content of the publication.

REFERENCES

1. Cardinale, D., Colombo, A., Lamantia, G., Colombo, N., Civelli, M., De Giacomi, G., Rubino, M., Veglia, F., Fiorentini, C., & Cipolla, C. M. (2010). Anthracycline-induced cardiomyopathy. *Journal of the American College of Cardiology, 55*(3), 213–220. https://doi.org/10.1016/j.jacc.2009.03.095
2. Curigliano, G., Cardinale, D., Suter, T., Plataniotis, G., de Azambuja, E., Sandri, M. T., Criscitiello, C., Goldhirsch, A., Cipolla, C., Roila, F., & ESMO Guidelines Working Group. (2012). Cardiovascular toxicity induced by chemotherapy, targeted agents and radiotherapy: ESMO Clinical Practice Guidelines. *Annals of Oncology, 23*(Suppl. 7), vii155–vii166. https://doi.org/10.1093/annonc/mds293
3. Du, H., Wang, J., & Wang, Z. (2025). Cardiovascular adverse effects of immunotherapy in cancer: Insights and implications. *Frontiers in Oncology, 15*, Article 1601808. https://doi.org/10.3389/fonc.2025.1601808
4. Ewer, M. S., & Ewer, S. M. (2015). Cardiotoxicity of anticancer treatments. *Nature Reviews Cardiology, 12*, 547–558. https://doi.org/10.1038/nrcardio.2015.65
5. Gan, L., Liu, D., & Ma, Y. (2022). Cardiotoxicity associated with immune checkpoint inhibitors. *Frontiers in Pharmacology, 13*, Article 962596. https://doi.org/10.3389/fphar.2022.962596
6. Minotti, G., Menna, P., Salvatorelli, E., Cairo, G., & Gianni, L. (2004). Anthracyclines: Molecular advances and pharmacologic developments. *Pharmacological Reviews, 56*(2), 185–229. https://doi.org/10.1124/pr.56.2.6
7. Ozaki, A. F., Sayer, M., & Hamano, H. (2025). Incidence and survival outcomes of myocarditis and pericardial diseases associated with immune checkpoint inhibitor therapy. *Cardio-Oncology, 11*, Article 26. https://doi.org/10.1186/s40959-025-00300-1
8. Swain, S. M., Whaley, F. S., & Ewer, M. S. (2003). Congestive heart failure in patients treated with doxorubicin. *Cancer, 97*(11), 2869–2879. https://doi.org/10.1002/cncr.11407
9. Zamorano, J. L., Lancellotti, P., Rodríguez Muñoz, D., Aboyans, V., Asteggiano, R., Galderisi, M., Habib, G., Lenihan, D. J., Lip, G. Y. H., Lyon, A. R., López Fernández, T., Mohty, D., Piepoli, M. F., Tamargo, J., & Torbicki, A. (2016). 2016 ESC Position Paper on cancer treatments and cardiovascular toxicity. *European Heart Journal, 37*(36), 2768–2801. https://doi.org/10.1093/eurheartj/ehw211
10. Armenian, S. H., Xu, L., Ky, B., Sun, C., Farol, L. T., Pal, S. K., Douglas, P. S., Bhatia, S., & Chao, C. (2016). Cardiovascular disease among survivors of adult-onset cancer: A community-based retrospective cohort study. *Journal of Clinical Oncology, 34*(10), 1122–1130. https://doi.org/10.1200/JCO.2015.64.0409

11. Herrmann, J. (2020). Adverse cardiac effects of cancer therapies: Cardiotoxicity and arrhythmia. *Nature Reviews Cardiology, 17*, 474–502. https://doi.org/10.1038/s41569-020-0348-1
12. Thavendiranathan, P., Poulin, F., Lim, K.-D., Plana, J. C., Woo, A., & Marwick, T. H. (2014). Use of myocardial strain imaging for the early detection of cardiotoxicity in patients during and after cancer chemotherapy. *Journal of the American College of Cardiology, 63*(25 Part A), 2751–2768. https://doi.org/10.1016/j.jacc.2014.01.073
13. Plana, J. C., Galderisi, M., Barac, A., Ewer, M. S., Ky, B., Scherrer-Crosbie, M., Ganame, J., Sebag, I. A., Agler, D. A., Badano, L. P., Banchs, J., Cardinale, D., Carver, J., Cerqueira, M., DeCara, J. M., Edvardsen, T., Flamm, S. D., Force, T., Griffin, B. P., Jerusalem, G., Liu, J. E., Magalhães, A., Marwick, T., Sanchez, L. Y., Sicari, R., Villarraga, H. R., & Lancellotti, P. (2014). Expert consensus for multimodality imaging evaluation of adult patients during and after cancer therapy. *Journal of the American Society of Echocardiography, 27*(9), 911–939. https://doi.org/10.1016/j.echo.2014.07.012
14. Sawaya, H., Sebag, I. A., Plana, J. C., Januzzi, J. L., Ky, B., Tan, T. C., Cohen, V., Banchs, J., Carver, J. R., Wiegers, S. E., Martin, R. P., Picard, M. H., Gerszten, R. E., Halpern, E. F., Passeri, J., Kuter, I., Scherrer-Crosbie, M. (2012). Assessment of echocardiography and biomarkers for the extended prediction of cardiotoxicity in patients treated with anthracyclines, taxanes, and trastuzumab. *Circulation: Cardiovascular Imaging, 5*(5), 596–603. https://doi.org/10.1161/CIRCIMAGING.112.973321
15. Cardinale, D., Colombo, A., Bacchiani, G., Tedeschi, I., Meroni, C. A., Veglia, F., Civelli, M., Lamantia, G., Colombo, N., Curigliano, G., Fiorentini, C., & Cipolla, C. M. (2015). Early detection of anthracycline cardiotoxicity and improvement with heart failure therapy. *Circulation, 131*(22), 1981–1988. https://doi.org/10.1161/CIRCULATIONAHA.114.013777
16. Ky, B., Putt, M., Sawaya, H., French, B., Januzzi, J. L., Jr., Sebag, I. A., Plana, J. C., Cohen, V., Banchs, J., Carver, J. R., Wiegers, S. E., Martin, R. P., Picard, M. H., Gerszten, R. E., Halpern, E. F., Passeri, J., Kuter, I., & Scherrer-Crosbie, M. (2014). Early increases in multiple biomarkers predict subsequent cardiotoxicity in patients with breast cancer treated with doxorubicin, taxanes, and trastuzumab. *Journal of the American College of Cardiology, 63*(8), 809–816. https://doi.org/10.1016/j.jacc.2013.10.061
17. Ganatra, S., & Neilan, T. G. (2018). Immune checkpoint inhibitor–associated myocarditis. *The Oncologist, 23*(8), 879–886. https://doi.org/10.1634/theoncologist.2018-0130
18. Heinzerling, L., Ott, P. A., Hodi, F. S., Husain, A. N., Tajmir-Riahi, A., Tawbi, H., Pauschinger, M., Gajewski, T. F., Lipson, E. J., Luke, J. J., Buchbinder, E. I., Chen, H., Barson, J. R., Pilotte, A. P., Heinzerling, J., Catini, J., Srivastava, R. M., Laurence, A., & Sullivan, R. J. (2016). Cardiotoxicity associated with CTLA-4 and PD-1 blocking immunotherapy. *Journal for ImmunoTherapy of Cancer, 4*, Article 50. https://doi.org/10.1186/s40425-016-0152-y
19. Johnson, D. B., Balko, J. M., Compton, M. L., Chalkias, S., Gorham, J., Xu, Y., Hicks, M., Puzanov, I., Alexander, M. R., Bloomer, T. L., Becker, J. R., Slosky, D. A., Phillips, E. J., Pilkinton, M. A., Craig-Owens, L., Kola, N., Plautz, G., Reshef, D. S., Deutsch, J. S., … Moslehi, J. J. (2016). Fulminant myocarditis with combination immune checkpoint blockade. *New England Journal of Medicine, 375*(18), 1749–1755. https://doi.org/10.1056/NEJMoa1609214